Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer-Reference-Cited by-同舟云学术

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer

Published:2021-12-01 Issue:12 Volume:7 Page:1791
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Llombart-Cussac Antonio¹²³,Pérez-García José Manuel²³⁴,Bellet Meritxell⁵,Dalenc Florence⁶,Gil-Gil Miguel⁷,Ruíz-Borrego Manuel⁸,Gavilá Joaquín⁹,Sampayo-Cordero Miguel²³,Aguirre Elena²³,Schmid Peter¹⁰,Marmé Frederik¹¹,Di Cosimo Serena²³¹²,Gligorov Joseph¹³,Schneeweiss Andreas¹⁴,Albanell Joan¹⁵¹⁶¹⁷¹⁸,Zamora Pilar¹⁹,Wheatley Duncan²⁰,Martínez-de Dueñas Eduardo²¹,Amillano Kepa²²,Malfettone Andrea²³,Cortés Javier²³⁴²³,Antón Antonio²⁴,Moiseyenko Vladimir²⁴,Cottu Paul²⁴,Viñas Gemma²⁴,Petit Thierry²⁴,Tesarova Petra²⁴,Vladimirov Vladimir²⁴,Cueva Bañuelos Juan²⁴,Colleoni Marco²⁴,Bertelli Gianfilippo²⁴,Martínez Purificación²⁴,Andres Raquel²⁴,Barannikova Tatiana²⁴,Servitja Sonia²⁴,Medioni Jacques²⁴,Cinieri Saverio²⁴,Bayo Juan²⁴,González Santiago²⁴,Melichar Bohuslav²⁴,Caranyana Vicente²⁴,Atzori Francesco²⁴,Beresford Mark²⁴,Chan Steven²⁴,Luque-Cabal Maria²⁴,de la Haba Juan²⁴,Bischoff Joachim²⁴,Mukhametsina Guzel²⁴,Cazzaniga Maria²⁴,Generali Daniele²⁴,Wardley Andrew²⁴,Cortesi Laura²⁴,Cavanna Luigi²⁴,Airoldi Mario²⁴,

Affiliation:

1. Hospital Arnau de Vilanova, Universidad Católica, Valencia, Spain

2. Medica Scientia Innovation Research, Barcelona, Spain

3. Medica Scientia Innovation Research, Ridgewood, New Jersey

4. International Breast Cancer Center Quiron Group, Barcelona

5. Vall d’Hebrón Institute of Oncology, Medical Oncology Department, Vall d’Hebrón University Hospital, Barcelona, Spain

6. Medical Oncology Department, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, Centre de recherches en cancérologie, Inserm, Toulouse, France

7. Medical Oncology Department, Institut Català d’Oncología, Insitut d’Investigació Biomèdica Bellvitge, Barcelona, Spain

8. Hospital Universitario Virgen del Rocío, Sevilla, Spain

9. Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain

10. Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, and Barts Hospital, NHS Trust, London, United Kingdom

11. University Hospital Heidelberg, Medical Faculty Mannheim Heidelberg University, Heidelberg, Germany

12. Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milano, Italy

13. Institut Universitaire de Cancérologie Assistance Publique–Hôpitaux de Paris, Sorbonne Université, Paris, France

14. National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany

15. Cancer Research Program, Hospital del Mar Research Institute, Barcelona, Spain

16. Medical Oncology Department, Hospital del Mar, Barcelona, Spain

17. Universitat Pompeu Fabra, Barcelona, Spain

18. Centro de Investigación Biomédica en Red de Oncología, Madrid, Spain

19. Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain

20. Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom

21. Medical Oncology Department, Hospital Provincial Castellón, Castelló De La Plana, Spain

22. Medical Oncology Department, Hospital Universitari Sant Joan de Reus, Reus, Spain

23. Vall d’Hebrón Institute of Oncology, Barcelona, Spain

24. for the PARSIFAL Steering Committee and Trial Investigators

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2784608/jamaoncology_llombartcussac_2021_oi_210064_1639155149.28618.pdf

Reference18 articles.

1. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).;Cardoso;Ann Oncol,2017

2. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.;Hortobagyi;Ann Oncol,2018

3. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.;Rugo;Breast Cancer Res Treat,2019

4. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.;Johnston;NPJ Breast Cancer,2019

5. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.;Di Leo;J Clin Oncol,2010

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer;Geburtshilfe und Frauenheilkunde;2024-09

2. Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5;Journal of Clinical Oncology;2024-08-01

3. Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer;The Breast;2024-08

4. A review of endocrine therapy for hormone-dependent breast cancer;Siberian journal of oncology;2024-07-07

5. Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer;European Journal of Clinical Pharmacology;2024-06-20